Psoriatic arthritis and cardiovascular diseases
F.N. RIZATDINOVA1, 2, D.I. ABDULGANIEVA2
1Republic Clinical Hospital, Kazan
2Kazan State Medical University, Kazan
Contact details:
Rizatdinova F.N. — cardiologist, postgraduate student of the Department of Hospital Therapy
Address: 138 Orenburgskiy trakt, Kazan, Russian Federation, 420064, tel.: +7-917-287-70-06, e-mail: rizatdinova.farida@yandex.ru
Psoriatic arthritis (PsA) is a chronic autoimmune disease that increases the risk of cardiovascular diseases (CVD) such as myocardial infarction, stroke, arrhythmias, and conduction disorders. Traditional risk factors such as hypertension, dyslipidaemia, and obesity may only partly explain the increased risk. Many factors, including chronic inflammation, metabolic syndrome, autonomic dysfunction, and endothelial dysfunction, may play a role in increasing the risk of CVD. PsA is associated with direct myocardial damage, left ventricular remodeling, electrocardiographic abnormalities, and arrhythmias, including fatal ones. This review considers the main CVDs, risk factors, the mechanisms of influence of PsA and its activity and phenotypes on these risk factors, as well as the possible interventions to reduce the risk of CVD in patients with PsA.
Key words: psoriatic arthritis, cardiovascular diseases, systemic inflammation.
REFERENCES
- Alinaghi F., Calov M., Kristensen L.E. et al.Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol, 2019, vol. 80 (1), pp. 251–265.e19. DOI: 10.1016/j.jaad.2018.06.027
- Ritchlin C.T., Colbert R.A., Gladman D.D. Psoriatic Arthritis. N Engl J Med, 2017, vol. 376 (10), pp. 957–970. DOI: 10.1056/NEJMra1505557
- Kibari A., Cohen A.D., Gazitt T. et al. Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study. Clin Rheumatol, 2019, vol. 38, pp. 2069–2075.
- Queiro R., Lorenzo A., Tejón P., Coto P., Pardo E. Obesity in psoriatic arthritis: Comparative prevalence and associated factors. Medicine (Baltimore), 2019, vol. 98 (28), p. e16400. DOI: 10.1097/MD.0000000000016400
- Husted J.A., Thavaneswaran A., Chandran V. et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken), 2011, vol. 63 (12), pp. 1729–1735. DOI: 10.1002/acr.20627
- Duan X., Liu J., Mu Y. et al. A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates. Medicine (Baltimore), 2020, vol. 99 (9), p. e19303. DOI: 10.1097/MD.0000000000019303
- Radner H., Lesperance T., Accortt N.A., Solomon D.H. Incidence and Prevalence of Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. Arthritis Care Res (Hoboken), 2017, vol. 69 (10), pp. 1510–1518. DOI: 10.1002/acr.23171
- Jafri K., Bartels C.M., Shin D. et al. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res, 2017, vol. 69, pp. 51–57.
- Badokin V.V., Kotel’nikova G.P. Heart damage in patients with psoriatic arthritis. Terapevticheskiy arkhiv, 2004, vol. 79, no. 5, pp. 56–61 (in Russ.).
- Giollo A., Farina N., Cioffi G. et al. Concentric left ventricular remodelling is associated with subclinical systolic dysfunction in patients with psoriatic arthritis. Scandinavian Journal of Rheumatology, 2020, vol. 49 (5), pp. 389–396. DOI: 10.1080/03009742.2020.1739328
- Egeberg A., Thyssen J.P., Jensen P. et al. Risk of Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis: A Nationwide Cohort Study. Acta Derm Venereol, 2017, vol. 97 (7), pp. 819–824. DOI: 10.2340/00015555-2657
- Polachek A., Touma Z., Anderson M., Eder L. Risk of Cardiovascular Morbidity in Patients with Psoriatic Arthritis: A Meta-Analysis of Observational Studies. Arthritis Care Res (Hoboken), 2017, vol. 69 (1), pp. 67–74. DOI: 10.1002/acr.22926
- Feld J., Weiss G., Rosner I., Rozenbaum M. et al. Electrocardiographic findings in psoriatic arthritis: a case-controlled study. J Rheumatol, 2008, vol. 35 (12), pp. 2379–2382. DOI: 10.3899/jrheum.080314
- Chiu H.Y., Chang W.L., Huang W.F. et al. Increased risk of arrhythmia in patients with psoriatic disease: A nationwide population-based matched cohort study. J Am Acad Dermatol., 2015, vol. 73 (3), pp. 429–438. DOI: 10.1016/j.jaad.2015.06.023
- Bengtsson K., Forsblad-d’Elia H., Lie E. et al. Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden. Ann Rheum Dis., 2018, vol. 77 (4), pp. 541–548. DOI: 10.1136/annrheumdis-2017-212189
- Ungprasert P., Srivali N., Kittanamongkolchai W. Psoriasis and risk of incident atrial fibrillation: A systematic review and meta-analysis. Indian J Dermatol Venereol Leprol, 2016, vol. 82, pp. 489–497.
- Rhee T.M., Lee J.H., Choi E.K. et al. Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study. Sci Rep, 2017, vol. 7 (1), p. 9973. DOI: 10.1038/s41598-017-10556-y
- Hakki Simsek, Musa Sahin, Aytac Akyol et al. Increased Risk of Atrial and Ventricular Arrhythmia in Long-Lasting Psoriasis Patients. The Scientific World Journal, 2013, vol. 2013. Article ID 901215, 5 p. DOI: 10.1155/2013/901215
- Park H.S., Laiz A., Díaz Del Campo P. et al. Prevalence and Risk for Bundle Branch Block, Atrioventricular Block and Pacemaker Implantation in Spondyloarthritis. A Systematic Review of the Literature. Front Med (Lausanne), 2022, vol. 9, p. 851483. DOI: 10.3389/fmed.2022.851483
- Bengtsson K., Forsblad-d’Elia H., Lie E. et al. Increased Risk of Atrioventricular Block, Atrial Fibrillation and Pacemaker Implantation in Ankylosing Spondylitis, Undifferentiated Spondylarthritis and Psoriatic Arthritis Compared to the General Population [abstract]. Arthritis Rheumatol, 2015, vol. 67 (10).
- Ferraz-Amaro I., Rueda-Gotor J., Genre F. et al. Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. Ther Adv Musculoskelet Dis, 2021, vol. 13. DOI: 10.1177/1759720X211033755
- Tasal A., Guvenc T.S., Kul S. et al. Atrial conduction abnormalities in patients with psoriasis vulgaris. Kardiol Pol, 2015, vol. 73 (8), pp. 637–643. DOI: 10.5603/KP.a2015.0028
- Soylu K., İnci S., Aksan G., Nar G. et al. Evaluation of in homogeneities of repolarization in patients with psoriasis vulgaris. Arch Med Sci, 2016, vol. 12 (6), pp. 1225–1231. DOI: 10.5114/aoms.2016.62922
- Simsek H., Sahin M., Akyol A. et al. Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis patients. Scientific World Journal, 2013, vol. 2013, p. 901215. DOI: 10.1155/2013/901215
- Namazi N., Helali M., Pishgahi et al. Assessment of P-wave indices as atrial fibrillation predictors in psoriasis patients. Iranian Journal of Dermatology, vol. 20, pp. 113–117.
- Sapsford M., Evans J., Clunie G., Jadon D. A comparison of clinical examination and ultrasound enthesitis indices in patients with psoriatic arthritis, adjusted for concomitant fibromyalgia. Ther Adv Musculoskelet Dis, 2021, vol. 13. doi: 10.1177/1759720X211003812
- Hjuler K.F., Gormsen L.C., Vendelbo M.H. et al. Systemic Inflammation and Evidence of a Cardio-splenic Axis in Patients with Psoriasis. Acta Dermato-Venereologica, vol. 98 (4), pp. 390–395. Doi: 10.2340/00015555-2873
- Queiro R., Lorenzo A., Tejón P. et al. Polyarticular evolution and late-onset psoriasis may be associated with cardiovascular disease in psoriatic arthritis. Int J Rheum Dis., 2019, vol. 22 (2), pp. 269–274. DOI: 10.1111/1756-185X.13421
- Tejón P., Morante I., Cabezas I. et al. A polyarticular onset and diabetes could be the main predictors of cardiovascular events in psoriatic arthritis. Clin Exp Rheumatol, 2016, vol. 34 (2), pp. 276–281.
- Popescu C., Pintilie A.M., Bojinca V. et al. Cardiovascular risk in psoriatic arthritis — a cross-sectional study. Maedica (Bucur), 2014, vol. 9 (1), pp. 19–24.
- Juneblad K., Rantapää-Dahlqvist S., Alenius G.M. Disease Activity and Increased Risk of Cardiovascular Death among Patients with Psoriatic Arthritis. J Rheumatol, 2016, vol. 43 (12), pp. 2155–2161. DOI: 10.3899/jrheum.160070.
- Eder L., Wu Y., Chandran V., Cook R., Gladman D.D. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann Rheum Dis, 2016, vol. 75 (9), pp. 1680–1686. DOI: 10.1136/annrheumdis-2015-207980
- Lorenzo A., Pardo E., Charca L. et al. Enthesitis and joint erosions are disease traits associated with cardiovascular risk in psoriatic arthritis. Clin Rheumatol., 2020, vol. 39 (10), pp. 2973–2979. DOI: 10.1007/s10067-020-05088-2
- Bakirci S., Dabague J., Eder L. et al. The role of obesity on inflammation and damage in spondyloarthritis: a systematic literature review on body mass index and imaging. Clin Exp Rheumatol, 2020, vol. 38 (1), pp. 144–148.
- Shrestha A., Bahce-Altuntas A., Mowrey W., Broder A. Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis. Semin Arthritis Rheum., 2016, vol. 46 (3), pp. 286–290. DOI: 10.1016/j.semarthrit.2016.05.011
- Armbruster A.L., Campbell K.B., Kahanda M.G., Cuculich P.S. The role of inflammation in the pathogenesis and treatment of arrhythmias. Pharmacotherapy, 2022, vol. 42 (3), pp. 250–262. DOI: 10.1002/phar.2663
- Lazzerini P.E., Capecchi P.L., Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J, 2017, vol. 38, pp. 1717–1727. DOI: 10.1093/eurheartj/ehw208
- Verheule S., Sato T., Everett T. 4th, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res, 2004, vol. 94 (11), pp. 1458–1465. DOI: 10.1161/01.RES.0000129579.59664.9d
- Liew R., Khairunnisa K., Gu Y. et al. Role of tumor necrosis factor-α in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ J, 2013, vol. 77 (5), pp. 1171–1179. DOI: 10.1253/circj.cj-12-1155
- Amdur R.L., Mukherjee M., Go A. et al. Interleukin-6 Is a Risk Factor for Atrial Fibrillation in Chronic Kidney Disease: Findings from the CRIC Study. PLoS One, 11, e0148189. DOI: 10.1371/journal.pone.0148189
- Marcus G.M., Whooley M.A., Glidden D.V. et al. Interleukin-6 and Atrial Fibrillation in Patients with Coronary Artery Disease: Data from the Heart and Soul Study. Am. Heart J., vol. 155, pp. 303–309. DOI: 10.1016/j.ahj.2007.09.006
- Dai R.P., Dheen S.T., Tay S.S. Induction of cytokine expression in rat post-ischemic sinoatrial node (SAN). Cell Tissue Res, 2002, vol. 310 (1), pp. 59–66. DOI: 10.1007/s00441-002-0596-x
- Deng H., Xue Y.M., Zhan X.Z. et al. Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrillation. Chin Med J (Engl), 2011, vol. 124 (13), pp. 1976–1982.
- Wu N., Xu B., Xiang Y., Wu L. et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int J Cardiol, 2013, vol. 169, pp. 62–72. DOI: 10.1016/j.ijcard.2013.08.078
- Marcus G.M., Whooley M.A., Glidden D.V. et al. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J, 2008, vol. 155 (2), pp. 303–309. DOI: 10.1016/j.ahj.2007.09.006
- Jia X., Cheng X., Wu N. et al. Prognostic value of interleukin-6 in atrial fibrillation: Acohort study and meta-analysis. Anatol J Cardiol, 2021, vol. 25 (12), pp. 872–879. DOI: 10.5152/AnatolJCardiol.2021.69299
- Li X., Peng S., Wu X. et al. C-reactive protein and atrial fibrillation: Insights from epidemiological and Mendelian randomization studies. Nutr Metab Cardiovasc Dis, 2022, vol. 32 (6), pp. 1519–1527. DOI: 10.1016/j.numecd.2022.03.008
- Peña J.M., MacFadyen J., Glynn R.J., Ridker P.M. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J, 2012, vol. 33 (4), pp. 531–517. DOI: 10.1093/eurheartj/ehr460
- Deftereos S., Giannopoulos G., Panagopoulou V. et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail, 2014, vol. 2 (2), pp. 131–137. DOI: 10.1016/j.jchf.2013.11.006
- Imazio M., Brucato A., Ferrazzi P. et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation, 2011, vol. 124 (21), pp. 2290–2295. Doi: 10.1161/CIRCULATIONAHA.111.026153
- Li J.Y., He Y., Ke H.H., Jin Y. et al. Plasma oxidative stress and inflammatory biomarkers are associated with the sizes of the left atrium and pulmonary vein in atrial fibrillation patients. Clin Cardiol, 2017, vol. 40 (2), pp. 89–94. DOI: 10.1002/clc.22633
- Conway D.S., Buggins P., Hughes E., Lip G.Y. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol, 2004, vol. 43 (11), pp. 2075–2082. DOI: 10.1016/j.jacc.2003.11.062
- Jalloul Y., Refaat M.M. IL-6 Rapidly Induces Reversible Atrial Electrical Remodeling by Downregulation of Cardiac Connexins. J Am Heart Assoc, 2019, vol. 8 (16), p. e013638. DOI: 10.1161/JAHA.119.013638
- Marcus G.M., Smith L.M., Glidden D.V. et al. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm, 2008, vol. 5 (2), pp. 215–221. DOI: 10.1016/j.hrthm.2007.10.007
- Daseke M.J. 2nd, Tenkorang M.A.A., Chalise U. et al. Cardiac fibroblast activation during myocardial infarction wound healing: Fibroblast polarization after MI. Matrix Biol, 2020, vol. 91–92, pp. 109–116. DOI: 10.1016/j.matbio.2020.03.010
- Haudek S.B., Taffet G.E., Schneider M.D., Mann D.L. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest, 2007, vol. 117 (9), pp. 2692–2701. DOI: 10.1172/JCI29134
- Blauvelt A., Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol, 2018, vol. 55 (3), pp. 379–390. DOI: 10.1007/s12016-018-8702-3
- Mizuguchi S., Gotoh K., Nakashima Y. et al. Mitochondrial Reactive Oxygen Species Are Essential for the Development of Psoriatic Inflammation. Front Immunol, 2021, vol. 12, p. 714897. doi: 10.3389/fimmu.2021.714897
- Viana V.S., de Carvalho J.F., de Moraes J.C. et al. Autoantibodies in patients with psoriatic arthritis on anti-TNFα therapy. Rev Bras Reumatol, 2010, vol. 50 (3), pp. 225–234.
- Zygadło J., Procyk G., Balsam P. et al. Autoantibodies in Atrial Fibrillation-State of the Art. Int J Mol Sci, 2023, vol. 24 (3), p. 1852. DOI: 10.3390/ijms24031852
- Liang K.P., Kremers H.M., Crowson C.S. et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol, 2009, vol. 36 (11), pp. 2462–2469. DOI: 10.3899/jrheum.090188
- Ryzhak G.A., Zheltysheva Zh.A. Metabolic syndrome impact on arrhythmias genesis in elderly women. Adv Gerontol, 2011, vol. 24 (4), pp. 658–662.
- Tkachenko L.I., Maleev V.V. The role of systemic inflammation in the pathogenesis of insulin resistance and metabolic syndrome in patients with chronic hepatitis C. Terapevticheskiy arkhiv, 2018, no. 11 (in Russ.).
- Syngle A., Verma I., Garg N., Krishan P. Autonomic dysfunction in psoriatic arthritis. Clin Rheumatol, 2013, vol. 32 (7), pp. 1059–1064. DOI: 10.1007/s10067-013-2239-x
- Gaydukova I., Rebrov A., Nikitina N., Poddubnyy D. Decreased heart rate variability in patients with psoriatic arthritis. Clin Rheumatol, 2012, vol. 31 (9), pp. 1377–1381. DOI: 10.1007/s10067-012-2015-3
- Schmidt M., Christiansen C.F., Mehnert F. et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ, 2011, vol. 343, p. d3450. DOI: 10.1136/bmj.d3450
- Myrvang H. Association between NSAIDs and risk of atrial fibrillation. Nat Rev Cardiol, 2010, vol. 7, p. 668. DOI: 10.1038/nrcardio.2010.173
- Brezinski E.A., Follansbee M.R., Armstrong E.J., Armstrong A.W. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des, 2014, vol. 20 (4), pp. 513–528. DOI: 10.2174/138161282004140213123852
- Singh M., Diwan M.M., Patel K.C. A rare case of supraventricular tachycardia induced by Infliximab: a case report. Cases J, 2009, vol. 2, p. 147. DOI: 10.1186/1757-1626-2-147
- Elnabawi Y.A., Oikonomou E., Dey A.K. et al. Association of Biologic Therapy with Coronary Inflammation in Patients with Psoriasis as Assessed by Perivascular Fat Attenuation Index. JAMA Cardiol, 2019, vol. 4, pp. 885–891.
- Wu J.J., Sundaram M., Cloutier M., Gauthier-Loiselle M. et al. The Risk of Cardiovascular Events in Psoriasis Patients Treated with Tumor Necrosis Factor-alpha Inhibitors versus Phototherapy: An Observational Cohort Study. Journal of the American Academy of Dermatology, 2018.
- Yang Z.S., Lin N.N., Li L., Li Y. The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis. Clin Rev Allergy Immunol, 2016, vol. 51 (2), pp. 240–247. doi: 10.1007/s12016-016-8560-9
- Garshick M.S., Ward N.L., Krueger J.G., Berger J.S. Cardiovascular Risk in Patients with Psoriasis: JACC Review Topic of the Week. J Am Coll Cardiol, 2021, vol. 77 (13), pp. 1670–1680. DOI: 10.1016/j.jacc.2021.02.009